Cargando…
The carboxyl terminus of VEGF-A is a potential target for anti-angiogenic therapy
Anti-VEGF-A therapy has become a mainstay of treatment for ocular neovascularisation and in cancer; however, their effectiveness is not universal, in some cases only benefiting a minority of patients. Anti-VEGF-A therapies bind and block both pro-angiogenic VEGF-A(xxx) and the partial agonist VEGF-A...
Autores principales: | Carter, James G., Gammons, Melissa V. R., Damodaran, Gopinath, Churchill, Amanda J., Harper, Steven J., Bates, David O. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4280485/ https://www.ncbi.nlm.nih.gov/pubmed/25274272 http://dx.doi.org/10.1007/s10456-014-9444-3 |
Ejemplares similares
-
Regulation of Vascular Endothelial Growth Factor (VEGF) Splicing from Pro-angiogenic to Anti-angiogenic Isoforms: A NOVEL THERAPEUTIC STRATEGY FOR ANGIOGENESIS
por: Nowak, Dawid G., et al.
Publicado: (2010) -
The endogenous anti-angiogenic VEGF isoform, VEGF(165)b inhibits human tumour growth in mice
por: Rennel, E S, et al.
Publicado: (2008) -
Altered ratios of pro‐ and anti‐angiogenic VEGF‐A variants and pericyte expression of DLL4 disrupt vascular maturation in infantile haemangioma
por: Ye, Xi, et al.
Publicado: (2016) -
Detection of VEGF-A(xxx)b Isoforms in Human Tissues
por: Bates, David O., et al.
Publicado: (2013) -
Anti-angiogenic alternatives to VEGF blockade
por: Khan, Kabir A., et al.
Publicado: (2015)